Tetramethylthiuram monosulfide

Tetramethylthiuram monosulfide (TMTM) is an orally active microsomal monooxygenases inhibitor. Tetramethylthiuram monosulfide is used as an accelerator and activator in the processing of natural rubber and butyl rubber. Tetramethylthiuram monosulfide reduces palmitic acid incorporation into microsomal phospholipids, disrupts microsomal membrane integrity, and impairs electron transport during oxygenation. Tetramethylthiuram monosulfide can be used for the research of fungal infection, bacterial infection and allergic contact dermatitis^[1][2]. In Vitro:Tetramethylthiuram monosulfide (10-2000 μg/plate; 48 h) induces point mutations in Salmonella typhimurium LT2 strains TA 100 and TA 1535 (especially with metabolic activation) and has a weak mutagenic effect in strain TA 1537, but does not induce mutations in strains TA 98 and TA 1538; higher doses exhibit bacteriotoxicity^[1].
Tetramethylthiuram monosulfide (0.2 ppm; 96 h) is cytotoxic to normal Hartley guinea pig lymph node cells at concentrations of 0.2 ppm and above when incubated with PHA stimulation^[2]. In Vivo:Tetramethylthiuram monosulfide (26-867 mg/kg; p.o.; single dose or 5 consecutive days per week for 4 weeks) inhibits rat hepatic microsomal monooxygenases at oral doses as low as 26 mg/kg, induces hematological, weight, and histopathological changes with 4-week 26 mg/kg/day dosing, and shows enhanced effects at 867 mg/kg^[1].
Tetramethylthiuram monosulfide (500-2500 mg/kg; p.o.; single dose) has an acute oral LD₅₀ of 818 mg/kg in adult female NMRI mice, with dose-dependent mortality and characteristic intoxication symptoms^[1].
Tetramethylthiuram monosulfide (5%; intradermal injection; epicutaneous via occlusive patch for sensitization; 2.0%; epicutaneous via Finn chamber, 24 hours for challenge) induces contact hypersensitivity in female Hartley guinea pigs, with 62.5% of sensitized animals displaying positive patch test reactions after epicutaneous challenge^[2].